|
A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons Clinical research trials and A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons. A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons clinical trial. Human subjects often receive the most effective healthcare possible for their A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons  A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons
A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Upjohn,Glaxo Wellcome
Synopsis: To determine the safety and tolerance of alvircept sudotox (sCD4-PE40) given at various dosing intervals and concentrations. To determine whether frequent dosing alters immunogenicity or toxicity. To obtain preliminary data to ascertain whether sCD4-PE40 has activity against HIV in human subjects. To determine whether there is any additive toxicity with combined use of sCD4-PE40 and zidovudine (AZT). There is some evidence that AZT and sCD4-PE40, an experimental drug with anti-HIV activity previously demonstrated in vitro, may produce increased benefit when used in combination in HIV-infected patients.
Details: There is some evidence that AZT and sCD4-PE40, an experimental drug with anti-HIV activity previously demonstrated in vitro, may produce increased benefit when used in combination in HIV-infected patients. Cohorts of six patients each receive escalating doses of sCD4-PE40 in a single IV weekly dose for 8 weeks. All six patients at a given dose must complete 2 weeks of therapy without dose-limiting toxicity before dose escalation in subsequent patient cohorts may occur. The MTD is defined as the dose of sCD4-PE40 immediately below that at which two or more of six patients experience grade 3 or higher toxicity or one or more of six patients experience grade 4 toxicity. After the MTD for the once-weekly schedule is reached, subsequent cohorts receive escalated doses of sCD4-PE40 on a 5x weekly schedule for approximately 4 weeks, in an attempt to establish the MTD for that schedule. When an MTD has been determined for the 5x weekly schedule, and if antiretroviral activity is observed, six additional patients receive this dose combined with AZT for 4 weeks.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - PCP prophylaxis with aerosolized pentamidine, trimethoprim / sulfamethoxazole, or dapsone. - Clotrimazole troches or nystatin oral suspension for oral candidiasis. - Acyclovir (up to 1000 mg/day for 10 days) for herpes lesions. - Erythropoietin. Patients must have: - Documented HIV infection by ELISA confirmed by a second method. If a prior diagnosis of AIDS has not been established by CDC criteria, a confirmatory test is required. - CD4 count = or < 300 cells/mm3 within 4 weeks prior to study entry. - Positive p24 antigen. Patients entering the AZT portion of the study only: - Must be AZT naive or have had less than 2 months of AZT therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Hemophilia. - Acute medical problems (including active opportunistic infections such as active cryptococcosis, Pneumocystis carinii, herpes zoster, histoplasmosis, or CMV or nonopportunistic diseases including liver disease, renal disease, or orthostatic hypotension) at time of study entry. - Active pulmonary disease. - Chronic active hepatitis B surface antigenemia or unstable hepatitis C. - Current diagnosis of malignancy for which systemic therapy would be required during the study. - Inadequate intravenous access. Concurrent Medication: Excluded: - Hepatotoxic agents. - Other antiretroviral or immunomodulator agents (including but not limited to AZT, ddI, ddC, interferon, and steroids). - Other investigational drugs. - Systemic therapy for malignancy. - G-CSF and GM-CSF. Prior Medication: Excluded: - Other antiretroviral or immunomodulator agents (including but not limited to AZT, ddI, ddC, interferon, and steroids) within 4 weeks prior to study entry. - Ribavirin within 90 days prior to study entry. - Cytotoxic chemotherapy within one month prior to study entry. - Prior soluble CD4 or CD4-Ig. Excluded in patients entering the AZT portion of the study: - More than 2 months of prior AZT therapy. Current active alcoholism or active substance abuse.
Total Enrollment: 64
Location and Contact Information:
Overall Study Official:
vanHorst C, Study Chair,
Univ of North Carolina
Chapel Hill, North Carolina, 275997215
United States
State of MD Div of Corrections / Johns Hopkins Univ Hosp
Baltimore, Maryland, 212052196
United States
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Tulane Univ Med School
New Orleans, Louisiana, 701122699
United States
Georgetown Univ Med Ctr
Washington D.C., District of Columbia, 20007
United States
UCLA CARE Ctr
Los Angeles, California, 90095
United States
Additional Information:
Study ID Numbers: ACTG 201;
Study Start Date:
Record last reviewed: July 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000743
Other Hiv Infections Studies:
1. The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
2. Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients with Hemophilia
3. HIV Symptom Management Program for African American Mothers
4. A Study of Megestrol Acetate Alone or in Combination with Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
5. A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Louisiana Clinical Trials
Other New Orleans Clinical Trials
A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons
|
|
|
|
|
|
|
|
